CRDL

Company Overview — What Does Cardiol Therapeutics Inc. Do?

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study; and LANCER design to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce major cardiovascular and respiratory events in patients hospitalized with COVID-19 that is in Phase II. The company is also developing a proprietary subcutaneous formulation of cannabidiol to achieve higher bioavailability for the treatment chronic heart failure. In addition, it develops proprietary nanotechnology to enable the distribution of water insoluble drugs within the blood circulation, enhance pharmacokinetics, and facilitate drug accumulation in the failing heart. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada. Cardiol Therapeutics Inc. (CRDL) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO David G. Elsley and employs approximately 20 people. With a market capitalization of $156M, CRDL is one of the notable companies in the Healthcare sector.

Cardiol Therapeutics Inc. (CRDL) Stock Rating — Hold (April 2026)

As of April 2026, Cardiol Therapeutics Inc. receives a Hold rating with a composite score of 33.7/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.CRDL ranks #1,484 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Cardiol Therapeutics Inc. ranks #127 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CRDL Stock Price and 52-Week Range

Cardiol Therapeutics Inc. (CRDL) currently trades at $1.40. The stock gained $0.02 (1.7%) in the most recent trading session. The 52-week high for CRDL is $1.59, which means the stock is currently trading -11.7% from its annual peak. The 52-week low is $0.77, putting the stock 82.1% above its annual trough. Recent trading volume was 453K shares, suggesting relatively thin trading activity.

Is CRDL Overvalued or Undervalued? — Valuation Analysis

Cardiol Therapeutics Inc. (CRDL) carries a value factor score of 19/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 9.10x, versus the sector average of 2.75x.

At current multiples, Cardiol Therapeutics Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Cardiol Therapeutics Inc. Profitability — ROE, Margins, and Quality Score

Cardiol Therapeutics Inc. (CRDL) earns a quality factor score of 29/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -593.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -460.4% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CRDL Debt, Balance Sheet, and Financial Health

Cardiol Therapeutics Inc. has a debt-to-equity ratio of 1.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $87,169. Cash and equivalents stand at $21M.

CRDL has a beta of 1.31, meaning it is more volatile than the broader market — a $10,000 investment in CRDL would be expected to move 30.7% more than the S&P 500 on any given day. The stability factor score for Cardiol Therapeutics Inc. is 33/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Cardiol Therapeutics Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Cardiol Therapeutics Inc. reported revenue of $0 and earnings per share (EPS) of $-0.35. Net income for the quarter was $-25M. Operating income came in at $-28M.

In FY 2024, Cardiol Therapeutics Inc. reported revenue of $0 and earnings per share (EPS) of $-0.35. Net income for the quarter was $-25M. Operating income came in at $-28M.

In FY 2023, Cardiol Therapeutics Inc. reported revenue of $0 and earnings per share (EPS) of $-0.33. Net income for the quarter was $-21M. Operating income came in at $-23M.

In FY 2022, Cardiol Therapeutics Inc. reported revenue of $0 and earnings per share (EPS) of $-0.49. Net income for the quarter was $-23M. Operating income came in at $-31M.

Over the past 6 quarters, Cardiol Therapeutics Inc. has experienced revenue contraction from $0 to $0. Investors analyzing CRDL stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CRDL Dividend Yield and Income Analysis

Cardiol Therapeutics Inc. (CRDL) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CRDL Momentum and Technical Analysis Profile

Cardiol Therapeutics Inc. (CRDL) has a momentum factor score of 49/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 57/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 9/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

CRDL vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Cardiol Therapeutics Inc. (CRDL) ranks #127 out of 838 stocks based on the Blank Capital composite score. This places CRDL in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CRDL against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CRDL vs S&P 500 (SPY) comparison to assess how Cardiol Therapeutics Inc. stacks up against the broader market across all factor dimensions.

CRDL Next Earnings Date

No upcoming earnings date has been announced for Cardiol Therapeutics Inc. (CRDL) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CRDL? — Investment Thesis Summary

Cardiol Therapeutics Inc. presents a balanced picture with arguments on both sides. The quality score of 29/100 flags below-average profitability. The value score of 19/100 indicates premium valuation. High volatility (stability score 33/100) increases portfolio risk.

In summary, Cardiol Therapeutics Inc. (CRDL) earns a Hold rating with a composite score of 33.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CRDL stock.

Related Resources for CRDL Investors

Explore more research and tools: CRDL vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CRDL head-to-head with peers: CRDL vs AZN, CRDL vs SLGL, CRDL vs VMD.